11/27
06:19 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
11/25
05:35 pm
rytm
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress [Seeking Alpha]
Low
Report
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress [Seeking Alpha]
11/25
07:19 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
11/10
04:00 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $105.00 to $114.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Canaccord Genuity Group Inc. from $105.00 to $114.00. They now have a "buy" rating on the stock.
11/10
08:18 am
rytm
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 [Yahoo! Finance]
11/10
07:00 am
rytm
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
Low
Report
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
11/7
07:30 am
rytm
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Low
Report
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
11/5
09:40 pm
rytm
Rhythm Pharmaceuticals (RYTM): Losses Have Averaged 18.8% Growth Annually; Revenue Forecast +45.8% Heading Into Earnings [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals (RYTM): Losses Have Averaged 18.8% Growth Annually; Revenue Forecast +45.8% Heading Into Earnings [Yahoo! Finance]
11/5
04:01 pm
rytm
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
Low
Report
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
11/5
05:01 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was downgraded by analysts at Oppenheimer Holdings, Inc. from an "outperform" rating to a "market perform" rating.
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was downgraded by analysts at Oppenheimer Holdings, Inc. from an "outperform" rating to a "market perform" rating.
11/4
08:08 pm
rytm
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/4
12:38 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $95.00 to $122.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $95.00 to $122.00. They now have a "buy" rating on the stock.
11/4
07:00 am
rytm
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
Medium
Report
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
10/21
04:01 pm
rytm
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Low
Report
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
10/17
08:13 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
10/16
10:05 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $129.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $129.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
9/29
07:02 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
9/25
10:17 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
9/25
10:17 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
9/25
09:34 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at JMP Securities from $135.00 to $142.00. They now have a "market outperform" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at JMP Securities from $135.00 to $142.00. They now have a "market outperform" rating on the stock.
9/25
05:00 am
rytm
Rhythm Pharmaceuticals: Exciting Times With sNDA PDUFA Date [Seeking Alpha]
Low
Report
Rhythm Pharmaceuticals: Exciting Times With sNDA PDUFA Date [Seeking Alpha]
9/24
05:23 pm
rytm
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses On Commercial Readiness For Acquired Hypothalamic Obesity Event Call (Transcript) [Seeking Alpha]
Low
Report
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses On Commercial Readiness For Acquired Hypothalamic Obesity Event Call (Transcript) [Seeking Alpha]
9/24
05:10 pm
rytm
Rhythm Pharmaceuticals, Inc. - Special Call [Seeking Alpha]
Low
Report
Rhythm Pharmaceuticals, Inc. - Special Call [Seeking Alpha]
9/24
02:19 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $105.00 to $138.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $105.00 to $138.00. They now have a "buy" rating on the stock.